



Cervical cancer accounts for **3.1% (604 127 new cases)** of the global cancer incidence and **3.3% (341 831 deaths)** of the global cancer mortality (Source: GLOBOCAN 2020).

This fact sheet presents the screening protocol, number of women screened and performance indicators according to the most up-to-date information received from **77 countries**.

The year of data collection may differ across the countries.

Reporting year	Screening test	Screening interval (years)	Age group	Number screened	Examination coverage (%)	Primary test positivity (%)	Further assessment participation rate (%)	Detection rate of CIN2+ (/1,000)	PPV of further assessment to detect CIN 2+ (%)	Treatment rate (%)
<b>AFRICA</b>										
Botswana	2020	VIA or cytology or HPV	5	30-49	—	—	—	—	—	—
Cabo Verde	2020	cytology	3	25-64	—	—	—	—	—	—
Cameroon	2019	VIA*	3	30-49	—	—	—	—	—	—
Côte d'Ivoire	2020	VIA*	5	25-55	41,166 <sup>#</sup>	2.1	4.2	—	—	—
Ethiopia	2020	VIA*	5	30-49	12,570 <sup>#</sup>	2.5	78.8	—	—	—
Kenya	2020	VIA*	5	25-49	—	—	—	—	—	—
Kenya	2020	cytology	5	25+	—	—	—	—	—	—
Libya	2021	<b>No programme</b>								
Morocco	2021	VIA	3	30-49	341,476 <sup>#</sup>	27.3	3.6	73.9	0.6	2.1
Mozambique	2020	VIA*	1	25-54	1,059,470	23.7	3.8	—	—	—
Namibia	2021	VIA*	1	20-49	—	—	—	—	—	—
Namibia	2021	cytology	1/2	25+	—	—	—	—	—	—
Rwanda	2020	VIA*	3	30-49	—	—	—	—	—	—
Rwanda	2020	HPV	3	30-49	—	—	—	—	—	—
South Africa	2020	cytology	10	30-50	1,025,681	—	6.0	—	—	—
South Africa	2020	VIA*	10	30-50	—	—	—	—	—	—
Uganda	2021	VIA*	3	25-49	—	—	—	—	—	—
United Republic of Tanzania	2020	VIA*	3	15-49	—	—	—	—	—	—
Zambia	2021	VIA*	3	25-59	—	—	—	—	—	—
Zambia	2021	HPV	5	25-49	—	—	—	—	—	—
Zimbabwe	2020	VIA*	3	18-69	130,066	19.1	5.9	—	—	54.6
<b>AMERICAS</b>										
Antigua and Barbuda	2021	<b>No programme</b>								
Bahamas	2020	cytology	3	21-65	—	—	—	—	—	—
Bahamas	2020	HPV+ cytology	5	30-69	—	—	—	—	—	—
Brazil	2020	cytology	3	25-64	—	—	—	—	—	—
Canada, Manitoba	2020	cytology	3	21-69	—	—	—	—	—	—
Colombia	2020	Mx	2	50-69	—	—	—	—	—	—
Colombia	2020	CBE	1	40-69	—	—	—	—	—	—
Chile	2020	HPV+ cytology	3	50-69	—	—	—	—	—	—
Chile	2020	cytology	3	25-64	—	—	—	—	—	—
Chile	2020	cytology	3	25-29	—	—	—	—	—	—
Colombia	2020	HPV	5	30-65	—	—	—	—	—	—
Colombia	2020	VIA*	3	30-50	—	—	—	—	—	—
Cuba	2021	cytology	3	25-64	866,363	81.7 <sup>†</sup>	2.1	—	—	—
Dominica	2021	<b>No programme</b>								
El Salvador	2020	cytology	2	20-99	—	—	—	—	—	—
El Salvador	2020	VIA*	5	30-59	—	—	—	—	—	—
Grenada	2021	cytology	3	21-55	—	—	—	—	—	—
Grenada	2021	VIA*	3	21-55	—	—	—	—	—	—
Guatemala	2021	cytology	3	25-54	—	—	—	—	—	—
Guatemala	2021	VIA*	3	25-40	—	—	—	—	—	—
Guatemala	2021	HPV	5	30-49	—	—	—	—	—	—
Guyana	2021	VIA*	3	25-49	2,931	—	6.2	—	—	82.3
Honduras	2020	VIA*	3	-49	—	—	—	—	—	—
Honduras	2020	cytology	1	50-99	—	—	—	—	—	—
Jamaica	2021	cytology	3	21-64	—	—	—	—	—	—
Mexico	2021	cytology	3	25-34	—	—	—	—	—	—
Mexico	2021	HPV	5	35-64	2,839,831 <sup>#</sup>	31.4	11.8	—	1.7	10.0
Nicaragua	2020	cytology	1	15-99	690,200	34.8	3.8	50.8	0.8 <sup>~</sup>	4.1 <sup>~</sup>
Nicaragua	2020	cytology	2	21-64	—	—	—	—	—	86.8 <sup>~</sup>
Panama	2020	HPV	3	25-64	—	—	—	—	—	—
Panama	2020	HPV + cytology	3	30-64	—	—	—	—	—	—
Paraguay	2020	cytology	1	-65	—	—	—	—	—	—
Paraguay	2020	HPV	5	30-64	—	—	—	—	—	—
Peru	2020	VIA*	2	30-49	—	—	—	—	—	—
Peru	2020	cytology	2	25-64	—	—	—	—	—	—
Peru	2020	HPV	5	30-49	—	—	—	—	—	—
Saint Lucia	2021	<b>No programme</b>								
Suriname	2021	VIA	1	23-99	—	—	—	—	—	—
Suriname	2021	cytology	3	50-99	—	—	—	—	—	—
Uruguay	2021	cytology	3	21-69	740,021	67.3	7.8	—	—	—
<b>ASIA</b>										
Bangladesh	2020	VIA	5	30-60	387,719	8.8	4.2	—	0.7 <sup>^</sup>	—
China, Henan	2021	cytology	5	35-64	—	—	—	—	—	—
India, Assam	2020	VIA	5	30-65	—	—	—	—	—	—
Japan	2020	cytology	2	20-99	4,294,127	15.7	2.1	—	2.9	19.1
Republic of Korea	2020	cytology	2	20-99	4,244,566 <sup>‡</sup>	47.4	2.7	—	0.3 <sup>^</sup>	—
Sri Lanka	2021	cytology	10	35-45	160,938	40.8	0.5	—	—	—
Sri Lanka	2021	HPV	10	35-45	—	—	—	—	—	—
Thailand	2019	Cytology	5	30-60	—	—	—	—	—	—
Thailand	2019	VIA	5	30-60	—	—	—	—	—	—
Turkey	2019	HPV	5	30-65	—	—	—	—	—	—

**Legend:**

HPV: human papillomavirus test; VIA: Visual inspection with acetic acid; \* Screen-and-treat protocol

<sup>#</sup> Target population is not the total of age eligible individuals for screening (sub-national), the project in Guyana is at the phase of rolling-out. <sup>†</sup> It might be slightly over estimated, because some participants outside of the screening programme were screened. <sup>^</sup> It might be slightly over estimated, because some participants outside of the screening programme were screened. <sup>~</sup> only for CIN3+. <sup>‡</sup> Women with a previous diagnosis of cancer prior to the examination date were excluded from this screened-related data. <sup>\*\*</sup> Colposcopy substantially part of screening primary visit



Cervical cancer accounts for **3.1% (604 127 new cases)** of the global cancer incidence and **3.3% (341 831 deaths)** of the global cancer mortality (Source: GLOBOCAN 2020).

This fact sheet presents the screening protocol, number of women screened and performance indicators according to the most up-to-date information received from **77 countries**.

The year of data collection may differ across the countries.

Reporting year	Screening test	Screening interval (years)	Age group	Number screened	Examination coverage (%)	Primary test positivity (%)	Further assessment participation rate (%)	Detection rate of CIN2+ (/1,000)	PPV of further assessment to detect CIN2+ (%)	Treatment rate (%)
<b>EUROPE</b>										
Austria	2016	cytology	1	18+	—	—	—	—	—	—
Belgium, Brussels and Wallonia	2013	cytology	3	25-64	—	—	—	—	—	—
Belgium, Flanders	2014	cytology	3	25-64	365,843	63.7	—	—	—	—
Bulgaria	2016	<b>No programme</b>								
Croatia	2013	cytology	3	25-64	42,694	10.3	—	—	—	—
Cyprus	2016	<b>No programme</b>								
Czechia	2013	cytology	1	15+	2,127,985	49.3	1.2	—	2.0	—
Denmark	2013	cytology	3	23-59	402,561	82.1	3.4	—	12.8	—
Estonia	2014	cytology	5	30-59	—	—	—	—	—	—
Finland	2012	cytology	5	30-64	164,878	66.0	0.9	98.8	2.6	29.3
France	2012	cytology	3	25-64	92,921	63.1	—	—	—	—
Germany	2012	cytology	1	20+	—	—	—	—	—	—
Greece	2016	<b>No programme</b>								
Hungary	2013	cytology	3	25-65	491,201	50.6**	90.9**	100.0**	—	—
Ireland	2013	cytology	3	25-60	165,247	47.4	—	—	—	—
Italy	2013	cytology	3	25-64	1,692,125	30.6	2.6	87.7	3.5	16.0
Latvia	2014	cytology	3	25-69	55,487	26.0	—	—	—	—
Lithuania	2014	cytology	3	25-59	91,905	46.9	—	—	—	—
Luxembourg	2013	cytology	1	18+	—	—	—	—	—	—
Malta	2013	cytology	3	25-35	—	—	—	—	—	—
Netherlands	2009	cytology	5	30-64	504,338	63.2	1.7	76.1	7.6	59.5
	2020	cytology	3	25-33	—	—	—	—	—	—
Norway	2020	HPV	5	34-69	—	—	—	—	—	—
Poland	2013	cytology	3	25-29	694,719	21.1	1.2	39.0	1.0	23.2
Portugal	2016	cytology	3	20-59	—	—	—	—	—	—
Portugal, Azores	2013	cytology	3	20-64	5,440	23.9	—	39.5	3.7	40.8
Romania	2016	Cytology	5	25-54	—	—	—	—	—	—
Slovakia	2016	<b>No programme</b>								
Slovenia	2013	cytology	2	20-64	164,364	77.4	0.8	80.7	4.4	65.4
Spain	2013	cytology	3	25-64	—	—	—	—	—	—
	2020	cytology	3	25-34	—	—	—	—	—	—
Spain, Basque Country	2020	HPV	5	35-65	—	—	—	—	—	—
Sweden	2013	cytology	3	23-60	629,728	86.3	5.1	66.0	9.5	28.4
United Kingdom, England	2013	cytology	3	25-64	3,225,180	79.3	6.2	—	—	—
United Kingdom, Northern Ireland	2013	cytology	3	25-64	118,893	85.7	—	—	—	—
United Kingdom, Scotland	2013	cytology	3	25-64	—	—	—	—	—	—
United Kingdom, Wales	2013	cytology	3	25-64	186,430	71.1	3.2	97.2	12.3	39.7
<b>OCEANIA</b>										
Australia	2018	HPV	5	25-74	3,129,719	—	8.3	—	5.2	47.6

